Subject category: 92. Pulmonary hypertension: primary
Introduction
Pulmonary hypertension (PH) is characterized by an increase in pulmonary vascular resistance that impedes the ejection of blood by the right ventricle and leads to right ventricular failure (1) . The pathogenesis of PH is complex and multifactorial. Progressive arterial wall thickening due to proliferation of endothelial and vascular smooth-muscle cells, vasoconstriction, and in situ thrombosis contribute to the marked elevation in pulmonary vascular resistance seen during PH progression. These pathological features are common to various forms of human PH, although they are more marked in idiopathic PH (iPH) (2) .
Several studies indicated involvement of serotonin (5-HT) in iPH and in PH associated with other diseases (2) . 5-HT is not only contained in platelets, but also synthesized by pulmonary endothelial cells (P-ECs), being thus available to act both on platelets and pulmonary-artery Overexpression of 5-HTT was described recently in various forms of PH in humans (6) , and PH develops spontaneously in transgenic mice overexpressing the 5-HTT gene in smoothmuscle cells (7) .
Recent pharmacological studies suggest that activation of the small G protein RhoA and its target Rho kinase is a critical shared mechanism in the pathogenesis of PH. In vivo, potent effects of treatment with Rho kinase inhibitor (Y-27632 or fasudil) have been demonstrated in several animal models of PH (8) (9) (10) (11) . In addition, the beneficial effect of sildenafil on PH is mediated, at least in part, by the inhibition of the RhoA/Rho kinase pathway (12) . In patients with PH, acute administration of low-dose fasudil reduced pulmonary vascular resistance and pulmonary arterial pressure (13, 14) . Recently, we demonstrated that 5-HT, internalized in vascular SMCs through the 5-HTT, was covalently linked to RhoA by intracellular type 2 Page 4 of 35 4 transglutaminase (TG2), leading to constitutive RhoA activation (15) . This process occurred in vivo in pulmonary arteries of rats in hypoxic conditions, thereby providing a link between 5-HTT and RhoA activation (15) . RhoA serotonylation following 5-HTT-mediated internalization of 5-HT was also described in platelets (16) . Important questions regarding the pathogenesis of PH are whether RhoA activation by 5-HT occurs both in platelets and PASMCs during progression of PH, whether this event contributes to PA-SMC proliferation, whether it is involved in the development of experimental PH and, more importantly, whether it is activated during human iPH progression.
The objectives of this study were to investigate RhoA activity and serotonylation in human PH, to assess the role for RhoA/Rho kinase activation in the growth-promoting effect of 5-HT in PA-SMCs, and to explore the role for this pathway in transgenic SM22-5-HTT + mice, which overexpress 5-HTT in vascular smooth muscle and spontaneously develop PH.
Methods

Tissue collection
Studies were performed on lung specimens and pulmonary arteries obtained from 15 patients with iPH, men and women aged 35 ± 9 years (rang 17 to 46 years). Lung specimens were obtained during lung transplantation. The mean pulmonary artery pressure in these patients was 64 ± 19 mm Hg (range, 31 to 85 mm Hg). All patients satisfied functional class III-IV criteria. Control lung specimens and pulmonary arteries were obtained from 10 patients undergoing surgery for localized lung cancer. Preoperative transthoracic echocardiography was performed in the controls to rule out PH. Platelets were obtained from blood collected in 5 separate patients with iPH (mean Pap 50 ± 10 mm Hg) and in 5 age-matched controls. The study was approved by our institutional review board.
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Culture of PA-SMCs
Pulmonary artery smooth muscle cells (PA-SMCs) were cultured from explants of pulmonary arteries obtained from iPH and control as previously described (17) .
Platelets preparation
Platelets were prepared from platelet-rich plasma (PRP) obtained by centrifugation (1300 rpm, 10 min) of blood samples collected from control and iPH patients. The platelet concentration in the PRP tended to be smaller in iPH patients ([430±51]x10 6 /mL) than in controls ([540±86]x10 6 /mL). PRP was centrifuged (5500 rpm, 10 min). The supernatant was discarded and platelets were stored at -80°C.
Measurements of PA-SMC Proliferation
PA-SMCs has been assessed by [ 
Western Blot Analysis
Western blot analysis of RhoA expression has been performed as described previously (15, 19) . Immunoreactive bands were revealed with HRP-conjugated secondary antibody, detected by ECL (Amersham) and quantified using QuantityOne (BioRad).
RhoA serotonylation
RhoA serotonylation was assessed by coimmunoprecipitation experiments as described in detailed previously (15) .
Measurement of RhoA/Rho kinase activity
The level of GTP-loaded RhoA has been assessed with the RhoA G-LISA kits (Cytoskeleton)
using the Rho-binding domain of the Rho effector Rhotekin. Rho kinase activity was quantified by western blot analysis for MYPT1 and phosphorylated MYPT1 using a rabbit polyclonal anti-phospho-MYPT1 (Thr696) (Upstate, Euromedex, Munolsheim, France).
Tension measurements in intact fibers
Contraction of pulmonary artery rings was recorded under isometric conditions as previously described (20) .
Production of SM22-5-HTT + and SM22-LacZ + Transgenic Mice.
Transgenic animals expressing the human 5-HTT gene in smooth muscle were produced as previously described (21) . All animal care and procedures were in accordance with institutional guidelines. Fasudil (30 mg/kg/day; LC Laboratories, Woburn, MA, USA) and fluoxetin (10 mg/kg/day) were administrated by gavage. At completion of treatment, lungs were removed and prepared as indicated for histological or Western blot analyses.
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Assessment of PH
Mice were studied at 20 weeks of age. Right ventricular (RV) systolic pressure was recorded and the Fulton index (right ventricle/left ventricle plus septum [RV/LV+S]) was determined as previously described (22) . Acute RV systolic pressure change in response to bolus injection of fasudil into the jugular vein (30 mg/Kg) was measured 5 min post-injection. The lungs were removed, fixed, and processed for paraffin embedding. The percentage of muscularized vessels was calculated as previously described (22) .
Chemicals and Drugs
Mouse monoclonal anti-RhoA antibody (26C4) and anti-MYPT1 antibodies were purchased from Santa Cruz Biotechnology, Inc. (CA, USA). Anti-5-HTT antibody was from Chemicon (Hampshire, UK) All other reagents were purchased from Sigma (Saint-Quentin Fallavier, France).
Statistical Analyses
Values are expressed as means ± SEM. Statistical analysis was performed by Student's t test or ANOVA. A P < 0.05 was considered significant.
Results
Activation of RhoA and Rho kinase in lung from patients with iPH
To asses the involvement of the RhoA/Rho kinase pathway in the pathogenesis of human iPH we directly analyzed Rho kinase activity by measuring the phosphorylation of MYPT, and
RhoA activity by measuring the amount of GTP-bound RhoA in human lung samples. As
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8 shown in Figure 1A , iPH is associated with a 2-fold increase in Rho kinase and RhoA activity, without change in the level of RhoA expression.
RhoA serotonylation in lungs from patients with iPH
RhoA serotonylation leads to constitutive RhoA activation and increased RhoA serotonylation was observed in pulmonary arteries of hypoxic rats (15) . To analyze the contribution of serotonylation to RhoA activation in human iPH, we therefore next analyzed serotonylation of RhoA immunoprecipitated from human lung samples by western blot with a specific anti-5-
HT. The amount of 5-HT that coimmunoprecipitated with RhoA was significantly increased in the lungs from patients with iPH compared to control samples ( Figure 1B ), indicating that
RhoA/Rho kinase activation is associated with RhoA serotonylation in iPH.
RhoA serotonylation and activation of the RhoA/Rho kinase in platelets from patients with iPH
RhoA serotonylation has been described in platelets (16) and platelets are involved in the pathogenesis of PH (23) . We therefore analyzed whether RhoA serotonylation was increased in platelets form iPH patients. Western blot analysis showed that the amount of 5-HT bound to immunoprecipitated RhoA was significantly higher in platelets from iPH patients than in control platelets ( Figure 2A ). This increase in RhoA serotonylation is associated with the activation of RhoA/Rho kinase, as demonstrated by the enhanced MYPT phosphorylation in platelets from patients with iPH ( Figure 2B ). 
Rho kinase inhibition reduces spontaneous PH in SM22-5HTT+ mice
To further assess the role of RhoA serotonylation and Rho kinase activation in the development of PH in relation to 5-HT, we next used SM22-5-HTT+ mice that overexpressed 5-HTT to an extent similar to that observed in PA-SMCs from patients with iPH (2-to 4-fold over control subjects) and spontaneously developed PH. (7) As shown in Figure 6 , the levels Taken together, these observations thus suggest a role of RhoA serotonylation-mediated Rho kinase activation in the development of PH.
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Discussion
Acute Rho kinase inhibition has been shown to reduce pulmonary vascular resistance and pulmonary arterial pressure in patients with severe PH, (13, 14) but the molecular basis for this effect has never been analyzed. Here, we show that RhoA and Rho kinase activity is up- RhoA activation by serotonylation. RhoA serotonylation corresponds to the covalent attachment of 5-HT to glutamine (Gln) residues, including Gln63, by TG2. Because Gln63 is essential for the intrinsic and GTPase-activating protein-stimulated GTPase activity of RhoA, serotonylated RhoA becomes constitutively active and can therefore trigger maintained 5-HT effects (15, 36, 37) . It has also been described that constitutive activation of RhoA led to its accelerated degradation and consequently to decrease its expression level (15) . Although not studied in detail here, it seems that RhoA expression in cells and tissues from iPH was slightly (20%) lower that than observed in control tissues, thus leaving a sufficient expression level of RhoA to underlay the maintained effects of 5-HT. 
